Group One Trading, L.P. Aveo Pharmaceuticals, Inc. Transaction History

Group One Trading, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$8.48 - $14.97 $290,507 - $512,842	34,258 New	34,258 $512,000
Q2 2022 Aug 11, 2022	SELL	$3.51 - $6.67 $80,687 - $153,329	-22,988 Reduced 74.89%	7,706 $51,000
Q1 2022 May 12, 2022	SELL	$3.15 - $6.01 $97,067 - $185,198	-30,815 Reduced 50.1%	30,694 $172,000
Q4 2021 Feb 11, 2022	BUY	$4.69 - $7.4 $103,663 - $163,562	22,103 Added 56.09%	61,509 $288,000
Q3 2021 Nov 12, 2021	SELL	$5.12 - $6.89 $50,222 - $67,584	-9,809 Reduced 19.93%	39,406 $244,000
Q2 2021 Aug 10, 2021	SELL	$6.21 - $7.45 $12,643 - $15,168	-2,036 Reduced 3.97%	49,215 $324,000
Q1 2021 May 12, 2021	BUY	$5.97 - $15.28 $305,968 - $783,115	51,251 New	51,251 $375,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.